XML 70 R61.htm IDEA: XBRL DOCUMENT v3.25.1

Commitments and Contingencies - Additional Information (Details) - USD ($)			1 Months Ended	3 Months Ended
	May 13, 2021	Dec. 02, 2020	Sep. 30, 2020	Mar. 31, 2025	Mar. 31, 2024	Oct. 31, 2016
Loss Contingencies [Line Items]
Research and development				$ 2,870,000	$ 2,040,000
Revenue Share Agreement | Oncimmune Limited
Loss Contingencies [Line Items]
Royalty expense				$ 400,000	200,000
Percentage of license agreement and royalty payment related to Nodify CDT test recognized revenue for non-screening tests				8.00%
Minimum annual volume percentage thereafter				5.00%
Bio-Rad License
Loss Contingencies [Line Items]
License fees				$ 0
License expiry date				2024-08
CellCarta License
Loss Contingencies [Line Items]
Percentage of royalty payments on net revenue	0.675%
Percentage of fee payments on net sales	1.00%
Term of royalty payments from first commercial sale	15 years
Year of ending royalty payments from first commercial sale	2034
Royalty expense				$ 100,000	100,000
AVEO Oncology
Loss Contingencies [Line Items]
Research and development				0	$ 0
Obligations related to agreement.				$ 0
AVEO Oncology | Ficlatuzumab
Loss Contingencies [Line Items]
Percentage of development and regulatory costs exercised using opt-out right			50.00%
Percentage of royalty payments on net sales		10.00%
Percentage of license income generated from licensing		25.00%
AVEO Oncology | NSCLC POC Trial
Loss Contingencies [Line Items]
Responsible percentage of development and regulatory costs						50.00%

X

- Definition

License agreement expiry date.

+ References

No definition available.

+ Details

Name:	bdsx_LicenseAgreementExpiryDate
Namespace Prefix:	bdsx_
Data Type:	xbrli:gYearMonthItemType
Balance Type:	na
Period Type:	duration

X

- Definition

License fees.

+ References

No definition available.

+ Details

Name:	bdsx_LicenseFees
Namespace Prefix:	bdsx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Minimum annual volume percentage thereafter.

+ References

No definition available.

+ Details

Name:	bdsx_MinimumAnnualVolumePercentageThereafter
Namespace Prefix:	bdsx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Obligations related to agreement.

+ References

No definition available.

+ Details

Name:	bdsx_ObligationsRelatedToAgreement
Namespace Prefix:	bdsx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Percentage of development and regulatory costs.

+ References

No definition available.

+ Details

Name:	bdsx_PercentageOfDevelopmentAndRegulatoryCosts
Namespace Prefix:	bdsx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Percentage of development and regulatory costs exercised using opt-out right.

+ References

No definition available.

+ Details

Name:	bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight
Namespace Prefix:	bdsx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of fee payments on net sales.

+ References

No definition available.

+ Details

Name:	bdsx_PercentageOfFeePaymentsOnNetSales
Namespace Prefix:	bdsx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of license income generated from licensing.

+ References

No definition available.

+ Details

Name:	bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing
Namespace Prefix:	bdsx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of revenue share payment related to nodify cdt test recognized revenue for non-screening tests.

+ References

No definition available.

+ Details

Name:	bdsx_PercentageOfRevenueSharePaymentRelatedToNodifyCdtTestRecognizedRevenueForNonScreeningTests
Namespace Prefix:	bdsx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of royalty payments on net revenue.

+ References

No definition available.

+ Details

Name:	bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue
Namespace Prefix:	bdsx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of royalty payments on net sales.

+ References

No definition available.

+ Details

Name:	bdsx_PercentageOfRoyaltyPaymentsOnNetSales
Namespace Prefix:	bdsx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Term of royalty payments from first commercial sale.

+ References

No definition available.

+ Details

Name:	bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale
Namespace Prefix:	bdsx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Year of ending royalty payments from first commercial sale.

+ References

No definition available.

+ Details

Name:	bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale
Namespace Prefix:	bdsx_
Data Type:	xbrli:gYearItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 720
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483359/720-20-50-1

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 27
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482395/460-10-55-27

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482425/460-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-1

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=bdsx_RevenueShareAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=bdsx_OncimmuneLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_BioRadLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_CellCartaLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_EquitySecuritiesByIndustryAxis=bdsx_FiclatuzumabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_NSCLCPOCTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: